Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma.
View/ Open
Volume
1
Pagination
43 - 54
DOI
10.2147/JHC.S48958
Journal
J Hepatocell Carcinoma
ISSN
2253-5969
Metadata
Show full item recordAbstract
Hepatocellular cancer (HCC) is currently the third leading cause of cancer death worldwide. The prognosis of patients diagnosed with late-stage disease is dismal due to high resistance to conventional systemic therapies. The introduction of sorafenib, despite its limited efficacy, as the standard systemic therapy for advanced HCC has paved a way for targeted molecular therapies for HCC. Fibroblast growth factor (FGF) signaling plays an important role in the developing embryo and the adult. The FGF signaling pathway is often hijacked by cancer cells, including HCC. Several alterations in FGF signaling correlate with poor outcome in HCC patients, suggesting that this family of signaling molecules plays an important role in the development of HCC. Multikinase inhibitors targeting FGF signaling are currently under investigation in clinical trials. This review discusses the current understanding of the biological and clinical implications of aberrant FGF signaling in the prognosis, diagnosis, and treatment of HCC.
Authors
Coleman, SJ; Grose, RP; Kocher, HMCollections
Language
Licence information
Copyright statements
The following license files are associated with this item: